SOPHiA GENETICS applies artificial intelligence and cloud computing to genomics. Founded in 2011 by biologists, the company builds technology that distils complex genomic data into actionable, real-time insights for clinicians, researchers and biopharma working on cancer and rare inherited disorders. Its technical work spans artificial intelligence, cloud computing, bioinformatics, data analytics and precision medicine, with applications in oncology and rare-disease diagnostics.
The firm's principal product, SOPHiA DDM™, is an AI-driven, cloud-powered platform designed to analyse complex molecular data and return insights usable in diagnosis and treatment. It is connected to more than 800 healthcare institutions across over 70 countries, giving engineering and data-science teams a global footprint in healthcare, diagnostics and life-sciences research.
SOPHiA GENETICS describes its purpose as democratizing data-driven medicine and securing equitable global access to precision medicine. The company frames its work around a "data for good" ethos and the belief that technology can have a lasting impact on healthcare outcomes.
